[go: up one dir, main page]
IDEAS home Printed from https://ideas.repec.org/e/pdu148.html
   My authors  Follow this author

Gautier DUFLOS

(We have lost contact with this author. Please ask them to update the entry or send us the correct address or status for this person. Thank you.)

Personal Details

First Name:Gautier
Middle Name:
Last Name:Duflos
Suffix:
RePEc Short-ID:pdu148
The above email address does not seem to be valid anymore. Please ask Gautier Duflos to update the entry or send us the correct address or status for this person. Thank you.
http://team.univ-paris1.fr/teamperso/duflos/gautier.htm

Affiliation

Théorie et Applications en Microéconomie et Macroéconomie (TEAM)
Centre d'Économie de la Sorbonne
Université Paris 1 (Panthéon-Sorbonne)

Paris, France
http://team.univ-paris1.fr/
RePEc:edi:teap1fr (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Gautier Duflos & Etienne Pfister, 2008. "Searching for innovations? the technological determinants of acquisitions in the pharmaceutical industry," Documents de travail du Centre d'Economie de la Sorbonne bla08057, Université Panthéon-Sorbonne (Paris 1), Centre d'Economie de la Sorbonne.
  2. Frank R. Lichtenberg & Gautier Duflos, 2008. "Pharmaceutical innovation and the longevity of Australians: a first look," NBER Working Papers 14009, National Bureau of Economic Research, Inc.
  3. Gautier Duflos, 2006. "Persistence of innovation, technological change and quality-adjusted patents in the US pharmaceutical industry," Cahiers de la Maison des Sciences Economiques bla06029, Université Panthéon-Sorbonne (Paris 1).

Articles

  1. Duflos, Gautier & Lichtenberg, Frank R., 2012. "Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization," International Review of Law and Economics, Elsevier, vol. 32(1), pages 95-109.
  2. Gautier Duflos & Étienne Pfister, 2007. "Les déterminants des fusions-acquisitions. Le cas de l'industrie pharmaceutique," Revue économique, Presses de Sciences-Po, vol. 58(3), pages 577-586.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Gautier Duflos & Etienne Pfister, 2008. "Searching for innovations? the technological determinants of acquisitions in the pharmaceutical industry," Documents de travail du Centre d'Economie de la Sorbonne bla08057, Université Panthéon-Sorbonne (Paris 1), Centre d'Economie de la Sorbonne.

    Cited by:

    1. Santosh K. Sahu & Nitika Agarwal, 2015. "Mergers and Acquisitions in the Indian Pharmaceutical Sector," Working Papers 2015-122, Madras School of Economics,Chennai,India.

  2. Frank R. Lichtenberg & Gautier Duflos, 2008. "Pharmaceutical innovation and the longevity of Australians: a first look," NBER Working Papers 14009, National Bureau of Economic Research, Inc.

    Cited by:

    1. Frank Lichtenberg, 2015. "Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010," CESifo Working Paper Series 5166, CESifo.
    2. Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
    3. Frank R. Lichtenberg, 2012. "The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files," NBER Working Papers 18552, National Bureau of Economic Research, Inc.
    4. Frank R. Lichtenberg, 2011. "The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007," NBER Working Papers 17414, National Bureau of Economic Research, Inc.
    5. Frank R. Lichtenberg, 2012. "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009," NBER Working Papers 18235, National Bureau of Economic Research, Inc.
    6. Branstetter, Lee G. & Kwon, Namho, 2018. "South Korea's transition from imitator to innovator: The role of external demand shocks," Journal of the Japanese and International Economies, Elsevier, vol. 49(C), pages 28-42.
    7. Lichtenberg, Frank R., 2014. "The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009," Economics & Human Biology, Elsevier, vol. 13(C), pages 107-127.
    8. Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer, 2014. "The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010," Health Policy, Elsevier, vol. 117(3), pages 361-373.

  3. Gautier Duflos, 2006. "Persistence of innovation, technological change and quality-adjusted patents in the US pharmaceutical industry," Cahiers de la Maison des Sciences Economiques bla06029, Université Panthéon-Sorbonne (Paris 1).

    Cited by:

    1. LE BAS Christian & MOTHE Caroline & NGUYEN Thi Thuc Uyen, 2011. "Technological innovation persistence: Literature survey and exploration of the role of organizational innovation," LISER Working Paper Series 2011-54, Luxembourg Institute of Socio-Economic Research (LISER).
    2. Christian Le Bas & Nicolas Poussing, 2012. "Are complex innovators more persistent than single innovators ? An empirical analysis of innovation persistence drivers," Working Papers halshs-00663788, HAL.
    3. Choi, Joonhwan & Lee, Jaegul, 2017. "Repairing the R&D market failure: Public R&D subsidy and the composition of private R&D," Research Policy, Elsevier, vol. 46(8), pages 1465-1478.
    4. Christian Le Bas & Caroline Mothe & Thuc Uyen Nguyen-Thi, 2015. "The differentiated impacts of organizational innovation practices on technological innovation persistence," Post-Print hal-01301433, HAL.
    5. Christian Le Bas & Caroline Mothe & Thuc Uyen Nguyen-Thi, 2015. "The differentiated impacts of organizational innovation practices on technological innovation persistence," Post-Print halshs-01497289, HAL.

Articles

  1. Duflos, Gautier & Lichtenberg, Frank R., 2012. "Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization," International Review of Law and Economics, Elsevier, vol. 32(1), pages 95-109.

    Cited by:

    1. Micael Castanheira De Moura & Carmine Ornaghi & Georges Siotis, 2019. "The Unexpected Consequences of Generic Entry," Working Papers ECARES 2019-21, ULB -- Universite Libre de Bruxelles.
    2. Frank R. Lichtenberg, 2019. "How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013," NBER Working Papers 25483, National Bureau of Economic Research, Inc.
    3. Daniel J. Hemel & Lisa Larrimore Ouellette, 2023. "The Generic Drug Trilemma," Entrepreneurship and Innovation Policy and the Economy, University of Chicago Press, vol. 2(1), pages 41-77.
    4. David Zimmer, 2018. "Did the Demand for Crestor Shrink when Lipitor’s Patent Expired?," Journal of Industry, Competition and Trade, Springer, vol. 18(2), pages 139-149, June.
    5. Frank R. Lichtenberg, 2014. "The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010," Journal of Human Capital, University of Chicago Press, vol. 8(4), pages 432-480.
    6. Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 3 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-COM: Industrial Competition (2) 2006-05-20 2008-11-25
  2. NEP-HEA: Health Economics (2) 2006-05-20 2008-05-17
  3. NEP-INO: Innovation (2) 2006-05-20 2008-11-25
  4. NEP-TID: Technology and Industrial Dynamics (2) 2006-05-20 2008-11-25
  5. NEP-AGE: Economics of Ageing (1) 2008-05-17
  6. NEP-CSE: Economics of Strategic Management (1) 2008-11-25
  7. NEP-ENT: Entrepreneurship (1) 2006-05-20
  8. NEP-IND: Industrial Organization (1) 2008-11-25
  9. NEP-IPR: Intellectual Property Rights (1) 2008-11-25
  10. NEP-KNM: Knowledge Management and Knowledge Economy (1) 2008-11-25
  11. NEP-MIC: Microeconomics (1) 2008-11-25

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Gautier Duflos should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.